医学
胰十二指肠切除术
内科学
阶段(地层学)
队列
瓦特壶腹
多元分析
回顾性队列研究
T级
辅助治疗
新辅助治疗
肿瘤科
胃肠病学
癌
化疗
癌症
胰腺
古生物学
乳腺癌
生物
作者
Orianne Colussi,Thibault Voron,Astrid Pozet,Pascal Hammel,Alain Sauvanet,Jean‐Baptiste Bachet,Jean‐Christophe Vaillant,P Rougier,Bernard Nordlinger,Adam C. Berger,Romain Coriat,B. Dousset,Deborah Malka,Thierry André,François Paye,Thomas Aparicio,C. Locher,D. Cojean Zeleck,L. Tchinou,Franck Bonnetain,Julien Taieb
出处
期刊:Ejso
[Elsevier]
日期:2015-04-01
卷期号:41 (4): 520-526
被引量:21
标识
DOI:10.1016/j.ejso.2015.01.010
摘要
Ampullary carcinoma (AC) is a relatively rare entity often managed as a biliopancreatic carcinoma. AC has a better prognosis than peri ampullary tumors after resection, but more than a third of patients relapse. Factors predictive of recurrence are controversial, mainly because the relevant studies are very small or also included non AC tumors. There are no guidelines on the use of adjuvant or neoadjuvant chemotherapy. The aim of this study was to identify prognostic factors for recurrence after AC resection in a large multicentric cohort, and to establish a simple, practical, predictive score for recurrence in order to guide multidisciplinary decisions.We included 152 consecutive patients who underwent Whipple's pancreaticoduodenectomy for ampullary carcinoma from January 2000 to December 2010 in 10 gastrointestinal oncology departments.The estimated overall 5-year disease-free survival rate (DFS) was 47.1%. In multivariate analysis, age≥ 75 years at diagnosis (p < 0.0001), poor general condition (p = 0.01), poorly (p = 0.005) or moderately differentiated tumors (p = 0.01) and TNM stage IIb or III (p = 0.05) were associated with poor DFS. Based on this multivariate analysis, we developed a prognostic score with three levels of risk: DFS at 5 years was 73.5% in the low-risk group and 20.1% in the high-risk group.This simple score based on age, general condition, tumor differentiation and TNM stage can classify patients into subgroups with different risks of recurrence and could help with therapeutic decisionmaking.
科研通智能强力驱动
Strongly Powered by AbleSci AI